Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses concerns surrounding cost and efficacy of molecular testing.
Andrew Norden, MD, MPH, MBA
Advertisement
Articles by Andrew Norden, MD, MPH, MBA
Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses differences between mCODE and Cota’s CNA Network.
Advertisement
Latest Updated Articles
Dr. Norden on Differences Between mCODE and Cota's CNA NetworkPublished: July 16th 2019 | Updated:
Dr. Norden on Cost and Effectiveness of Genomic TestingPublished: January 22nd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5